Search Results - daniel+urban

2 Results Sort By:
Treatment of primary hyperoxalurias with small molecule lactate dehydrogenase inhibitors such as WO2018005807A1
This technology includes the use of novel lactate dehydrogenase (LDH) inhibitors, including WO2018005807A1, for the treatment of primary hyperoxalurias (PHs). PHs are rare autosomal recessive disorders caused by overproduction of oxalate, leading to recurrent calcium oxalate kidney stone disease, and in some cases end-stage renal disease. One potential...
Published: 10/28/2024   |   Inventor(s): Daniel Urban, Leonard Neckers, Ross Holmes, David Wood, Matthew Hall
Keywords(s): DEHYDROGENASE, Hyperoxalurias, Inhibitors, LACTATE, MOLECULE, Primary, Small, TREATING, VPXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Cardiology, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Research Materials
A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer
This technology includes the design, synthesis, and use of a novel chemical series for multiple treatments, including for treating cancer. A series of substituted bicyclic heteroaryl small molecules were found to be a potent inhibitor of bromodomain-containing protein 4 (BRD4) for multiple uses, including cancer. A BRD4 inhibitor is in a class of drugs...
Published: 10/28/2024   |   Inventor(s): David Maloney, Shyh-Ming Yang, Ajit Jadhav, Daniel Urban, Makoto Yoshioka, Jeffrey Strovel
Keywords(s): BICYCLIC, Brd4, Bromodomain-containing, Heteroaryl, Inhibitors, Protein, Substituted, VCXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Oncology, Application > Therapeutics